ProMIS Neurosciences Inc.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$39.7M
- Total assets
- $9.2M
- Market cap
- $81.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $40.2M
- Operating income
- -$40.2M
- Net income
- -$39.7M
- EPS (basic)
- $-22.61
- EPS (diluted)
- $-22.61
Balance sheet
- Total assets
- $9.2M
- Current assets
- $9.2M
- Total liabilities
- $10.4M
- Current liabilities
- $10.4M
- Shareholders’ equity
- -$1.3M
Cash flow
- Operating cash flow
- -$28.1M
- Investing cash flow
- -$702
- Financing cash flow
- $20.9M
- Net cash flow
- -$7.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $81.9M
- EPS (diluted)
- $-22.61
- Shares outstanding
- 8.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 30, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.7M.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ProMIS Neurosciences Inc..
Write a review
News about ProMIS Neurosciences Inc.
News & sentiment via Polygon.io
